Bakirtas, MehmetDal, Mehmet SinanYigenoglu, Tugce NurGiden, Asli OdabasiSerin, IstemiBasci, SemihKalpakci, Yasin2024-04-242024-04-2420231120-009X1973-9478https://doi.org/10.1080/1120009X.2023.2208439https://hdl.handle.net/11468/16925A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.eninfo:eu-repo/semantics/closedAccessProteasome InhibitorsIxazomibLenalidomideMultiple MyelomaTurkeyMulticenterArticle356563569WOS:0009947065000013721190610.1080/1120009X.2023.2208439N/A